Sayama

Biotech Investor

[Sayama @Sayamabio]

Huge milestone in the history of chemical synthesis with yeast, Congrats Jay Keasling, and team!
"It is the longest biosynthetic pathway ever refactored into yeast"
https://t.co/yo3gmDA4Q7

[Sayama @Sayamabio]

Hi, Lycia Therapeutics/LYTAC

[Sayama @Sayamabio]

Dear people with a biology background
If you want to rethink your career, why not take a look at this map drawn up by RA Cap's TECHATLAS team?
https://t.co/NFl7m1wLp6

[Sayama @Sayamabio]

More reports on DDS optimization using multi-omics analysis are sure to follow in the future.

[Sayama @Sayamabio]

Now that the importance of DDS has been demonstrated, it would be natural for its optimization to come next
Recent two Science/NatBiotech papers on functional analyses of nanoparticle formulations clearly capture trends
https://t.co/wmtGnrqiIp

[Sayama @Sayamabio]

This report describes a way of barcoding LNP, measuring delivery to cells, doing a functional screen on how much of the mRNA delivered/protein expression via a specific formulation, and doing a scRNA-seq to look at the transcriptome of transfected cells
https://t.co/hv8GgJjVPM

[Sayama @Sayamabio]

21 biotechs pay more than midian $350k...!

[Andrew Dunn @AndrewE_Dunn]

Biotechs with the highest median employee pay for 2021:

1. Kodiak Sciences: $1,656,424
2. Anavex Life Sciences: $753,041
3. Axsome: $690,964
4. Cortexyme: $622,098
5. Karuna: $511,630

Check out the full list of 21 — all above $350K — here:
https://t.co/Y0MRFKZ1KP

[Sayama @Sayamabio]

New Perspective in NEJM on image-activated cell sorting by Anne Carpenter!
https://t.co/dH95Uf6zLg

[Sayama @Sayamabio]

Despite the technological advances in cell engineering, we are still analyzing cells using FACS, which was reported more than 50 years ago.
Now is the time to sort cells based on intracellular features!
Congrats BD Bio (Omega Biosystem) team!
https://t.co/IYM2byDs9o

[Sayama @Sayamabio]

DeepCell announced $73M series B, Koch Disruptive, Bridger Healthcare, Horizons Ventures, Casdin Capital A16Z, and Bow Capital as well as Jeff Dean, Head of Google Brain!
Congrats, Maddison Masaeli, and team!
https://t.co/lZ5G8jlTYf

[Sayama @Sayamabio]

RA Cap opened "RA University"
They have gathered all of RA Cap’s educational materials in one place, so whether you're interested in exploring new concepts or would like to revisit some familiar topics, you need only to register for a free account.
https://t.co/dxOdINeRic

[Sayama @Sayamabio]

@KRAS_MYC_P53 NovartisのKRASiデータも出てきましたし、MiratiのSOS1iも面白そうでしたね
Covalent KRAS G12Dも250nMは少し高いなあと思いつつ、vivoでも効果がでてるのでその内臨床に来るでしょう
正直どれが優れた薬効を示すか現時点では分かりませんが笑、今後に期待ですね

[Sayama @Sayamabio]

@KRAS_MYC_P53 Mirati含め他社があの手この手でnon-covalent inhibitor作ったのに、もうcovalentが出てくるんですね笑
構造は公開されていないようですが、分子量とか気になります！

[Sayama @Sayamabio]

@KobyMd いえ、こちらこそいつも勉強させていただいています
たまたま関連のトピックで検索かけて眺めていたらTweetをお見かけて差し出がましいコメントをしてしまいました
どうぞ引き続き宜しくお願い申し上げます

[Sayama @Sayamabio]

Carlyle acquired Abingworth - another big PE player joined biotech investment
https://t.co/ytUUaMbqxz

[Sayama @Sayamabio]

Endurance and perseverance of hardships for the next surge

[FierceBiotech @FierceBiotech]

Chutes & Ladders: Fierce Biotech launches Layoff Tracker amid dizzying number of industry job cuts
https://t.co/ZdnICCc2U6

[Sayama @Sayamabio]

Terrific work, and a great resource for anyone interested in partial reprogramming to capture past achievements and the current landscape!

[Ada Nguyen @adanguyenx]

There is a lot of excitement around partial reprogramming, especially with the launch of @altos_labs. But how promising is it exactly?

I spent the last three months reading almost all the papers in the field. 13k words later, we have:
https://t.co/xAhQcIBJz8

[Sayama @Sayamabio]

Building a global biotech: Taking a first-time launch into international markets

"Among drugs launched internationally, markets outside the United States accounted for about 35 percent of total revenues."
https://t.co/CrRsd0ePMy

[Sayama @Sayamabio]

- JPM slides
https://t.co/HxjrFSADD3

[Sayama @Sayamabio]

ex-Juno members raised big round for hacking both traditional immunology subtypes CD4+/CD8+ T cells for KRAS G12V and KRAS G12D
Debuted at the JPM Conference with initial data, and it raised $175M!
https://t.co/sI0HuafOFz